Consensus and controversies regarding the treatment of rhabdomyosarcoma

Scott C. Borinstein, Diana Steppan, Masanori Hayashi, David M. Loeb, Michael S. Isakoff, Odion Binitie, Andrew S. Brohl, Julia A. Bridge, Mark Stavas, Eric T. Shinohara, William H. Meyer, Damon R. Reed, Lars M. Wagner

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.

Original languageEnglish (US)
Article numbere26809
JournalPediatric Blood and Cancer
Volume65
Issue number2
DOIs
StatePublished - Feb 1 2018

    Fingerprint

Keywords

  • adolescent and young adult
  • chemotherapy
  • pediatric
  • rhabdomyosarcoma
  • sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Borinstein, S. C., Steppan, D., Hayashi, M., Loeb, D. M., Isakoff, M. S., Binitie, O., Brohl, A. S., Bridge, J. A., Stavas, M., Shinohara, E. T., Meyer, W. H., Reed, D. R., & Wagner, L. M. (2018). Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatric Blood and Cancer, 65(2), [e26809]. https://doi.org/10.1002/pbc.26809